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ABSTRACT
Antineutrophil cytoplasmic antibodies (ANCA) are autoantibodies directed against primary granules of neutrophils
and monocytes’ lysosomes. In general, c-ANCA is strongly associated with vasculitic disorders mainly in ANCA-associated
systemic vasculitis (AASV). p-ANCA have been identified in several diseases such as primary (AASV) and secondary
vasculitis such as collagen vascular diseases, rheumatoid arthritis and inflammatory bowel diseases given the term
‘ANCA-associated disease.’ The objective of this study was to determine the rate of ANCA positivity by indirect
immunofluorescent (IF) and enzyme linked immunosorbent assay (ELISA) and its association with AASV and ANCA
associated diseases. Serum from patients with history suspicion of systemic vasculitis were tested for ANCA by IF. Those
samples positive for ANCA by IF were further tested for antibodies against myeloperoxidase (MPO) and proteinase 3
(PR3) using the ELISA. Clinical data from medical records were obtained and analyzed. Of 468 samples, a total of 110
were positive for ANCA by IF. IF results showed a p-ANCA pattern in 96 patients and c-ANCA in 14. Of 110 IF positive ANCA,
45 patients were positive by ELISA. Seventeen were positive for MPO-ANCA, 9 were PR3-ANCA positive and 19 were both
MPO and PR3 positive. Only 2 patients were classified AASV ie Wegener granulomatosis and the other with microscopic
polyangiitis. The remaining patients (n = 108) may be classified as ANCA associated diseases. Our study showed that p-
ANCA (87.3%) was the more common ANCA pattern and 40.9% of IF positive samples were positive for PR3- and MPO-
ANCA.
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ABSTRAK
Antineutrofil antibodi sitoplasma (ANCA) merupakan antibodi terhadap granul primer di dalam lisosom neutrofil dan
monosit. Secara amnya, c-ANCA berkaitan dengan penyakit radang salur darah terutama radang salur darah sistemik
berkaitan ANCA (AASV). p-ANCA diidentifikasi di dalam beberapa penyakit seperti penyakit radang salur darah jenis
primer (AASV) dan sekunder iaitu penyakit salur darah kolagen, sendi rheumatoid dan penyakit inflamasi usus yang
dirumuskan sebagai penyakit berkaitan ANCA. Untuk memgetahui kadar positif ANCA melalui ujian imunofluoresen
secara tidak langsung (IF) dan ujian menggunakan enzim imunosorben (ELISA) dan hubungannya dengan penyakit
AASV dan penyakit berkaitan ANCA. Serum pesakit yang disyaki mempunyai penyakit radang salur darah sistemik
disaring dengan ujian IF. Ujian ELISA dijalankan ke atas sampel ANCA yang positif dengan ujian IF untuk mengesan
antibodi terhadap spesifisiti antigen ANCA iaitu “myeloperoxidase” (MPO) dan “proteinase 3” (PR3). Data daripada
rekod pesakit dicatit dan dianalisa. Daripada 468 sampel yang diterima, sebanyak 110 serum didapati positif dengan
ujian IF. Keputusan IF menunjukkan p-ANCA seramai 96 pesakit dan c-ANCA seramai 14 orang. Daripada jumlah 110
positif IF, 45 pesakit positif dengan ujian ELISA iaitu 17 orang adalah MPO, 9 orang PR3 dan 19 orang mempunyai
kedua-dua MPO dan PR3. Dua pesakit dikategorikan sebagai penyakit AASV iaitu “Wegener’s granulomatosis” dan
“Microscopic polyangiitis”. Selebihnya (n = 108) adalah di dalam kategori Penyakit Berkaitan ANCA. Kajian ini
menunjukkan p-ANCA (87.3%) merupakan “pattern” IF yang sering dijumpai dan sebanyak 40.9% sampel positif IF
yang mengandungi antibodi terhadap PR3- dan MPO-ANCA.
Kata kunci: Antineutrofil antibodi sitoplasma; p-ANCA; c-ANCA; Myeloperoxidase; Peroxidase 3
INTRODUCTION
ANCA are predominantly immunoglobulin G (IgG)
autoantibodies directed against constituents of primary
granules of neutrophils and monocytes’ lysosomes. ANCA
were first described as diffuse granular cytoplasmic
immunofluorescence staining (c-ANCA) on ethanol-fixed
neutrophils in association with glomerulonephritis,
vascultitis and Wegener’s granulomatosis (Bosch et al.
2006). Proteinase 3 (PR3) was subsequently identified as
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the principal target antigen for these ANCA. At the same
time, ANCAs reacting to myeloperoxidase (MPO) and
resulting in a perinuclear immunofluorescence staining
pattern on ethanol-fixed neutrophils (p-ANCA) which were
found in patients with microscopic polyangiitis, its renal-
limited variant, pauci-immune glomerulonephritis and less
frequently, in Wegener’s granulomatosis (Savige et al. 2000).
Laboratory tests for ANCA are used when a systemic
vasculitis or renopulmonary syndrome is suspected
clinically. Today, Wegener’s granulomatosis (WG),
microscopic polyangiitis (MPA) and the Churg-Strauss
syndrome (CSS) are commonly referred to as the ANCA-
associated systemic vasculitides (AASV) or primary systemic
small vessel vasculitides. In general, c-ANCA is strongly
associated with vasculitic disorders mainly in ANCA-
associated systemic vasculitis (AASV). p-ANCA have been
identified in several diseases such as primary (AASV) and
secondary vasculitis such as collagen vascular diseases,
rheumatoid arthritis and inflammatory bowel diseases given
the term ‘ANCA-associated disease.’ (Jenette et al. 1994;
Seo & Stone 2004).
The overall incidence of AASV is approximately 10-20
per million populations and the majority of data on the
incidence and prevalence of AASV has come from studies
in the United Kingdom, France, Norway, Sweden and
Germany. In these populations AASV is slightly more
common in men (1.5:1.0) and the peak onset is in those
aged 65 to 74 years. AASV is rare in childhood (Lane et al.
2005).
Despite advances in ANCA testing techniques,
histopathology remains the gold standard for diagnosis in
most cases. When the biopsy specimen is not diagnostic,
ANCA assays provide an important adjunct to diagnosis
(Seo & Stone 2004).
The “International Consensus Statement on Testing
and Reporting of ANCA” has been developed to optimize
the usefulness of ANCA testing and to ensure more
uniformity in the laboratory results that are issued. It
stipulates that all sera should at least be tested by indirect
immunofluorescent (IF) examination of normal peripheral
blood neutrophils and, where there is positive IF, an enzyme-
linked immunosorbent assays (ELISAs) should be
performed for antibodies against proteinase 3 (PR3) and
myeloperoxidase (MPO) (Savige et al. 1999).
In Malaysia, routine tests for ANCA employed either IF
or ELISA. Thus, the aims of this study were: 1) to determine
the frequency of ANCA positivity using two different
methods ie. IF for pattern and ELISA for specific target to
PR3 and MPO; 2) to describe the clinical features of ANCA
associated diseases.
MATERIAL AND METHODS
STUDY POPULATION
This was a cross-sectional study comprising of 468
consecutive sera from patients in Selayang Hospital,
Malaysia with suspicious systemic vasculitis from June
2005 until July 2006 were tested for ANCA by IF test. Samples
were tested at the Institute for Medical Research. Those
samples positive for ANCA by IF were further tested for
antibodies against myeloperoxidase (MPO) and proteinase
3 (PR3) using the ELISA test. The study was approved by
the Research and Ethical Committee of the Medical Faculty,
Universiti Kebangsaan Malaysia (UKM).
CLINICAL DATA
Complete clinical data and laboratory results were
documented. Diseases were classified either as primary
systemic small vessel vasculitides (Wegener’s
Granulomatosus (WG), microscopic polyangitis (MPA),
Churg-Strauss syndrome) according to Chapel Hill
Consensus definition or other diseases (such as systemic
lupus erythematosus, rheumatoid arthritis, inflammatory
bowel disease and other disease process).
METHODS
Immunofluorecence All serum samples were tested for
ANCA using the kit from Immuno Concepts (USA) for the
semi quantitative detection of anti-neutrophil cytoplasmic
antibodies (ANCA) in human serum. Diluted patient samples
were incubated with human neutrophils, which are fixed on
glass microscope slides, to allow specific binding of ANCA.
If ANCA are present in the serum, the autoantibodies bind
to neutrophilic antigens. After washing to remove non-
specific antibodies, the antigen-antibody complex is
incubated with anti-human IgG conjugated to fluorescein.
Fluorescence patterns were defined as c-ANCA when giving
a diffuse granular cytoplasmic staining and as p-ANCA when
giving a diffuse or peripheral nuclear staining of the
neutrophils on ethanol fixed cells.
Enzyme-linked immunosorbent assay (ELISA) All IF ANCA
positive samples were assayed subsequently, by ELISA
(BINDAZYMETM, Binding Site, UK), to determine the precise
antigen specificity of the autoantibody present (anti-MPO
and anti-PR3). The microwells were pre-coated with the
MPO/PR3 antigen. The calibrators, controls and diluted
patient samples were added to the wells. After washing the
wells to remove all unbound proteins, purified peroxidase
labelled rabbit anti-human IgG (γ chain specific) conjugate
was added. The conjugate bound to the captured human
autoantibody and the excess unbound conjugate is removed
by a further wash step. The bound conjugate is visualized
with 3,3’5,5’ tetramethylbenzidine (TMB) substrate which
gives a blue reaction product, the intensity of which is
proportional to the concentration of autoantibody in the
sample. Phosphoric acid is added to each well to stop the
reaction. This produces a yellow end point colour that is
read at 450 nm. Results more than 3.5 U/mL and 9.0 U/mL
were considered positive to PR3 and MPO respectively.
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RESULTS
ANCA RESULTS
A total of 110 out of 468 (23.5%) serum samples were positive
for ANCA by IF. Of these, 96 samples showed a p-ANCA IF
pattern (Figure 1) and 14 showed a c-ANCA pattern (Figure
2). Only 45 out of 110 samples (40.9%) tested positive by
ELISA. 17 samples were positive to MPO-ANCA, 9 to PR3-
ANCA and 19 to both MPO- and PR3-ANCA.
TABLE 1. Diagnosis of ANCA positive patients
Disease Number of patients
SLE 40
CLD (consists of)
1) Autoimmune hepatitis 8
2) Hepatitis B virus infection 8
3) Primary billiary cirrhosis 5
4) Hepatitis C virus infection 3
5) Unknown aetiology 9
Total CLD patients 33
Rheumatoid arthritis 10
Drug induced hepatitis 7
Scleritis 4
Nephrotic syndrome 3
Scleroderma 3
Mixed connective tissue disease 2
Non-specific diagnosis 2
ITP 1
Pulmonary hypertension 1
Crohn’s disease 1
Wegener’s granulomatosis 1
Microscopic polyangiitis 1
Malignancy 1
Total (Bold numbers) 110
FIGURE 1: p-ANCA IF pattern on ethanol-fixed neutrophils
FIGURE 2. c-ANCA IF pattern on ethanol-fixed neutrophils
DEMOGRAPHICS OF ANCA POSITIVE SAMPLES
Females comprised 74.5% of the study population and males
25.5%. Out of 110 patients, 57.3% were Malays, 27.3% were
Chinese, 14.5% were Indian and 0.9% other races. The mean
age of the study group was 38 years.
ANCA POSITIVE SAMPLES ACCORDING TO DIAGNOSIS
Out of 110 patients with a positive ANCA, 40 patients were
diagnosed as systemic lupus erythematosus (SLE). Two
patients were diagnosed as ANCA-associated systemic
vasculitis (AASV) ie. Wegener granulomatosis and
microscopic polyangiitis. Table 1 showed the clinical
diagnosis among positive ANCA patients.
ANCA RESULTS AND OTHER AUTOIMMUNE TESTS
Most positive ANCA patients (n = 49) also had other
autoimmune tests done. 49 patients were anti-nuclear
antibody positive. The association between ANCA and other
autoantibodies were shown in Table 2.
DISCUSSION
It is important that the main antigen involved in the c-
ANCA pattern is PR3, and the main antigen producing the
p-ANCA pattern is MPO (Savige et al. 1999). However, our
findings indicate 57/96 (59.4%) of p-ANCA and 8/14 (57.1%)
of c-ANCA positive samples were negative for MPO and
PR3. This finding suggests that antibodies targeting antigen
other than MPO and PR3 may be involved.
Human neutrophils contain at least three types of
granules, each of which contains a variety of constituent
proteins: azurophilic granules contain PR3, MPO,
bactericidal permeability increasing protein/BPI, elastase/
Elast, cathepsin G/Cath G; secondary granules contain
lactoferrin/LF, lysozyme; and tertiary granules contain
gelatinase. Antigens within any of these granules are
potential targets for an ANCA response. ‘Minor’ antigens
involved all the above granules except PR3 and MPO (Roos
et al. 1990). Talor et al. (2007) examined antibodies to minor
antigens such as anti-BPI, anti-Elast, anti-Cath G and anti-
LF using enzyme immunoassay (EIA) in patients with ANCA.
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They found that IF positivity with negative MPO and PR3
ELISA sera showed the most varied reactivity to the minor
antigens. Our results implied that ANCA testing by IF would
also detect other ANCA minor antigens based on lack of
association between IF and ELISA for MPO and PR3.
ANCA are serological markers for a significant subset
of patients with primary systemic small vessel vasculitis
known as ANCA-associated small vessel vasculitides (AASV),
which include Wegener’s granulomatosis, microscopic
polyangiitis and Churg-Strauss syndrome. In this study,
only two patients with positive ANCA were diagnosed with
AASV ie. one patient with Wegener granulomatosis and
another with microscopic polyangiitis. Other patients with
positive IF ANCA fall under the category of ANCA associated
diseases.
Our study showed that 40 patients (36.4%) with
positive ANCA were diagnosed with SLE. In another study
done in Malaysia by Fauzi et al. (2004), they reported ANCA
was present in 24.8% of SLE patients. They found that there
was no association between ANCA positivity and disease
activity, thus routine testing for ANCA in lupus patients is
therefore not recommended. While ANCA may be detected
in SLE, its detection does not provide any additional
diagnostic or prognostic data. (Molnar et al. 2002).
In this study, there were 33 patients with chronic liver
disease (CLD). Savige et al. (2005) reported that ANCA are
prevalent in CLD patients (70% patients with chronic
autoimmune hepatitis and 90% patients with primary
sclerosing cholangitis). These are usually p-ANCA and with
multiple antigen specificities.
Amongst the rheumatoid arthritis (RA) patients
(n = 10), 8 patients were positive for p-ANCA and 2 patients
were positive to c-ANCA. However none of them had any
antigen specificities to MPO or PR3. The lack of association
between IF result and ELISA among RA patients in our study
may suggest that the ANCA are targeting ‘minor’ antigens
instead. In a study carried out by Birkan et al. (2004), they
found that the prevalence of ANCA was 18% and only 8 out
of 85 patients with RA tested were positive for MPO. They
concluded that ANCA occurred in a minority of RA patients.
Analysis of association between ANCA results and
other autoantibodies showed that among 96 patients with
p-ANCA, 49 had antinuclear antibody (ANA). In primary
systemic small vessel vasculitides, ANA were shown to
occur in up to 30% of patients, and these IF pattern vary
and may mask a p-ANCA (Savige et al. 2000). In this study,
interference by ANA is eliminated as the IF test for p-ANCA
is done using fixation of cells in formalin.
We evaluated all requests for ANCA testing from
Selayang Hospital and noted several issues. Out of 468
requests for ANCA tests, only two were categorized as AASV
and 108 patients were only ANCA-associated diseases. The
prevalence of AASV in Selayang hospital was considered
very rare (0.43%). In both cases of AASV, the
immunoflouresecence and ELISA tests were positive for
ANCA. This highlighted the importance of ANCA testing in
the diagnosis of AASV. We noted that most of the requests
for ANCA testing were not to diagnose AASV but to rule out
autoimmune diseases. If tests are ordered for patients with
a high suspicion for AASV, the number of positive results
will be meaningful.
In conclusion, the prevalence of primary systemic
small vessel vasculitides in Selayang hospital was
considered rare. Our study showed that p-ANCA 96/10
(87.3%) was common for ANCA pattern and only 45/110
(40.9%) of IF ANCA positive samples were positive for PR3-
and MPO-ANCA.
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TABLE 2. Association between ANCA and other autoantibodies
ANCA pattern ANCA antigen specificity
Autoimmune tests P-ANCA C-ANCA MPO PR3 MPO & PR3
no (%) no (%) no (%) no (%) no (%)
Antinuclear antibody (n = 49) 49 (100) 0 7 (14) 5 (10) 9 (18)
Anti-double stranded DNA (n = 21) 21 (100) 0 3 (14) 3 (14) 3 (14)
Rheumatoid factor (n = 17) 15 (88) 2 (12) 0 2 (12) 2 (12)
Antimitochondrial antibody (n = 16) 14 (88) 2 (12) 2 (22) 3 (19) 5 (36)
Anti-SSM (n = 18) 18 (100) 0 5 (28) 2 (11) 1 (56)
Anti-RNP (n = 8) 8 (100) 0 0 2 (25) 2 (25)
Anti-cardiolipin antibody (n = 6) 6 (100) 0 1 (17) 0 0
Anti-sm (n = 4) 4 (100) 0 0 0 1 (25)
Lupus anticoagulant (n = 2) 2 (100) 0 0 0 0
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